<DOC>
	<DOCNO>NCT00052455</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know regimen chemotherapy effective treating recurrent malignant glioma . PURPOSE : Randomized phase III trial compare effectiveness temozolomide alone procarbazine , lomustine , vincristine treat patient recurrent malignant glioma .</brief_summary>
	<brief_title>Temozolomide Compared Procarbazine , Lomustine , Vincristine Treating Patients With Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy temozolomide vs procarbazine , lomustine , vincristine , term overall survival , patient recurrent malignant glioma . - Compare progression-free survival patient treat regimen . - Compare progression-free survival 12 week patient treat two different schedule temozolomide . - Compare overall survival patient treat two different schedule temozolomide . - Compare toxic effect two different schedule temozolomide patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , control , open-label , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients randomize 1 2 treatment schedule : - Schedule 1 : Patients receive oral temozolomide daily day 1-5 . - Schedule 2 : Patients receive oral temozolomide daily day 1-21 . Treatment schedule repeat every 4 week maximum 9 course absence disease progression unacceptable toxicity . - Arm II : Patients receive oral lomustine vincristine IV day 1 oral procarbazine day 1-21 . Treatment repeat every 6 week maximum 6 course absence disease progression unacceptable toxicity . Quality life assess baseline 12 24 week . Patients follow every 12 week . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 500 patient ( 250 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm anaplastic astrocytoma , glioblastoma multiforme , gliosarcoma WHO grade III IV diagnosis relapse Must undergone primary therapy include radiotherapy Must first recurrence confirm CT scan MRI Evaluable disease CT scan MRI PATIENT CHARACTERISTICS : Age 18 Performance status WHO 03 Life expectancy At least 1 month Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Total direct bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 3 time ULN Alkaline phosphatase less 2 time ULN Renal BUN less 1.5 time ULN Creatinine less 1.5 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious illness Considered fit receive chemotherapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy glioma Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 2 month since prior radiotherapy No prior radiosurgery , interstitial radiotherapy , brachytherapy glioma Surgery Prior debulking surgery recurrent disease allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>